LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

Начало・Списък с акции・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Затворен

СекторЗдравеопазване

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-0.05% downside

Настроения в новините

By Acuity

58%

42%

266 / 344 Класиране в Healthcare

Mirati Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.05.2026 г., 21:33 ч. UTC

Печалби

Correction to Salesforce 1Q Sales, Profit Rise Article

27.05.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Agrees to Buy The College of Health Care Professions

27.05.2026 г., 20:18 ч. UTC

Печалби

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27.05.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

27.05.2026 г., 23:08 ч. UTC

Пазарно говорене

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27.05.2026 г., 22:21 ч. UTC

Пазарно говорене

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27.05.2026 г., 21:29 ч. UTC

Горещи акции

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27.05.2026 г., 21:08 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27.05.2026 г., 21:02 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27.05.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27.05.2026 г., 20:55 ч. UTC

Печалби

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.05.2026 г., 20:48 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27.05.2026 г., 20:45 ч. UTC

Печалби

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27.05.2026 г., 20:34 ч. UTC

Придобивния, сливания и поглъщания

Webster Financial Stockholders Approve Sale to Banco Santander

27.05.2026 г., 20:32 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27.05.2026 г., 20:30 ч. UTC

Печалби

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27.05.2026 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27.05.2026 г., 20:22 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:16 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27.05.2026 г., 20:13 ч. UTC

Печалби

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Сравнение с други в отрасъла

Ценова промяна

Mirati Therapeutics Inc Прогноза

Ценова цел

By TipRanks

-0.05% надолу

12-месечна прогноза

Среден 58.67 USD -0.05%

Висок 59 USD

Нисък 58 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Mirati Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Mirati Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

266 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.